Acquisitions (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended		3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended		9 Months Ended						0 Months Ended
	Jun. 27, 2014	Jun. 28, 2013	Jun. 27, 2014	Jun. 28, 2013	Apr. 05, 2014 Questcor Pharmaceuticals, Inc.	Oct. 31, 2012 CNS Therapeutics, Inc.	Jun. 27, 2014 Specialty Pharmaceuticals Questcor Pharmaceuticals, Inc.	Jun. 27, 2014 Specialty Pharmaceuticals Questcor Pharmaceuticals, Inc.	Mar. 19, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Jun. 27, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Jun. 27, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Oct. 01, 2012 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Jun. 27, 2014 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Jun. 28, 2013 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Jun. 27, 2014 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Jun. 28, 2013 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Jun. 27, 2014 H. P. Acthar Gel Questcor Pharmaceuticals, Inc. pharmacy_indications	Jun. 27, 2014 Licensing Agreements Ofirmev Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Jun. 27, 2014 Secured Debt Term Loan	Mar. 19, 2014 Secured Debt Term Loan	Mar. 19, 2014 Completed Technology Ofirmev Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Total consideration					$ 6,000,000,000				$ 1,300,000,000			$ 95,000,000
Cash per share					30				14
Mallinckrodt shares to be issued per Questcor share					0.897
Number of FDA approved indications																	19
Acquisition costs							16,600,000	17,500,000			17,600,000
Acquisition funding, term loan, face amount																				1,300,000,000.0
Discount rate used, completed technology																					13.00%
Net sales	653,100,000	570,000,000	1,751,100,000	1,659,300,000						53,200,000	58,500,000		8,700,000	7,500,000	24,100,000	20,800,000
Income (loss) from continuing operations before income taxes	(26,700,000)	(7,900,000)	27,700,000	82,500,000						57,600,000	66,600,000
Interest rate																			3.50%
Cash payment, net of cash acquired			1,303,200,000	88,100,000								88,100,000
Cash and cash equivalents									43,200,000			3,600,000
Contingent consideration						6,900,000						6,900,000
Contingent consideration, potential maximum						9,000,000						9,000,000
Future milestone payments																		$ 25,000,000